EGFR-IN-176
EGFR-IN-176 is an orally active and ATP-competitive EGFR mutant inhibitor (particularly C797S-mediated EGFR triple mutant). EGFR-IN-176 effectively inhibits subsequent AKT signaling and induces apoptosis in Ba/F3 and PC-9 cells expressing EGFR19del/T790M/C797S and EGFRL858R/T790M/C797S. EGFR-IN-176 selectively inhibits EGFR signaling in cell lines harboring EGFR triple mutation and shows no inhibitory effect against A431 cells that express wild-type EGFR. EGFR-IN-176 can effectively inhibit the enzymatic activity of ALK (IC50 < 0.5 nM). EGFR-IN-176 can be used for the study of non-small cell lung cancer (NSCLC).
For research use only. We do not sell to patients.
- CAS No.: 2754394-10-8
- Formula: C35H45N11O3S
- Molecular Weight:699.87
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All EGFR Isoforms
More
Biological Activity
Description
In Vitro
EGFR-IN-176 (Compound 31r, 0.0045 nM-10,000 nM, 48 h) exhibits extremely potent and selective growth inhibitory activity against cells harboring EGFR triple mutation in vitro, including Ba/F3 EGFR19del/T790M/C797S (IC50 = 0.001 nM) and Ba/F3 EGFRL858R/T790M/C797S (IC50 = 0.04 nM), with low cytotoxicity towards wild-type EGFR cells A431 (IC50 > 10,000 nM)[1].
EGFR-IN-176 (500 nM, 7 days) inhibits PC-9 EGFR19del/T790M/C797S and PC-9 EGFRL858R/T790M/C797S proliferation in the short term and deprives cancer cells of their self-renewal and clonogenic growth capabilities in the long term[1].
EGFR-IN-176 (250 nM, 0-24 h) can effectively inhibit the migration ability of PC-9 EGFR19del/T790M/C797S and PC-9 EGFRL858R/T790M/C797S[1].
EGFR-IN-176 (500 nM, 48 h) can induce PC-9 EGFR19del/T790M/C797S and PC-9 EGFRL858R/T790M/C797S apoptosis[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Ba/F3 EGFR19del/T790M/C797S and Ba/F3 EGFRL858R/T790M/C797S
-
Concentration:0.0045 nM ~ 10,000 nM
-
Incubation Time:48 h
-
Result:Exhibited higher activity, with IC50 values of 0.001 nM (Ba/F3 EGFR19del/T790M/C797S) and 0.04 nM (Ba/F3 EGFRL858R/T790M/C797S).
-
Cell Line:PC-9 EGFR19del/T790M/C797S and PC-9 EGFRL858R/T790M/C797S
-
Concentration:250 nM
-
Incubation Time:24 h
-
Result:Significantly slowed down the healing rate of scratches.
-
Cell Line:PC-9 EGFR19del/T790M/C797S and PC-9 EGFRL858R/T790M/C797S
-
Concentration:500 nM
-
Incubation Time:48 h
-
Result:significantly increased the proportion of early and late apoptotic cells
Parmacokinetics
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Subcutaneously inoculate the right forelimb of 6-8-week-old BALB/c-nu mice with a 0.2 mL suspension of PC-9 EGFR19del/T790M/C797S cells at a concentration of 2.5×10^7 cells/mL until the tumor volume reaches 100-200 cubic millimeters.
-
Dosage:40 mg/kg, 60 mg/kg, 80 mg/kg
-
Administration:Oral gavage, once daily for 21 days
-
Result:Showed a dose-dependent tumor growth inhibitory effect, the tumor growth inhibition rates (TGI) were 80.2% (40 mg/kg), 92.3% (60 mg/kg), and 105.7% (80 mg/kg), respectively.
Observed tumor regression in the high-dose group (80 mg/kg), the tumor volume decreased to below the initial volume.
Exhibited favorable in vivo tolerability, with no mortality or significant body weight loss observed.
Significantly inhibited EGFR phosphorylation and the activation of downstream signaling pathways.
Chemical Information
-
CAS No. 2754394-10-8
-
Molecular Weight 699.87
-
Formula C35H45N11O3S
-
SMILES
O=S(N(C)C1=C2N=CC=NC2=CC=C1NC3=C4C=CNC4=NC(NC5=C(OC)C=C(N6CCC(CC6)N7CCN(CC7)C)C(CC)=C5)=N3)(C)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Genotoxicity/Mutagenicity Study
The bacterial reverse mutation assay detects point mutations that restore amino-acid prototrophy in auxotrophic Salmonella typhimurium or Escherichia coli tester strains; after exposure to a test article, mutagenic activity is read out as an increased number of revertant colonies on minimal agar compared with the vehicle control. The assay uses tester strains with different mutation targets so that base-substitution and frameshift mutagens can be detected, and testing is performed with and without exogenous mammalian metabolic activation because some chemicals require biotransformation to become mutagenic.
-
Directly Induced Neuron Culture
Directly induced neuron culture converts somatic cells, most commonly fibroblasts, into induced neurons without passing through a pluripotent or neural progenitor stage; classic evidence shows that mouse fibroblasts can be converted by Ascl1, Brn2/Pou3f2, and Myt1l, human fibroblasts can be converted by defined neuronal transcription factors, and human fibroblasts can also be converted by miR-9/9-124 with neurogenic or subtype-specifying transcription factors. The readout is acquisition of neuronal identity and function, assessed by neuronal morphology, neuronal markers such as Tuj1/βIII-tubulin, MAP2, synapsin, and subtype markers when relevant, together with functional assays such as action-potential firing, synaptic activity, and electrophysiology.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)